Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients

Biomarker Research

Jean Jacques N. Noubiap²  Mickael Essouma¹ 

[1]Division of Medicine, Sangmelima Referral Hospital, Sangmelima, Cameroon

[2]Medical Diagnostic Center, Yaoundé, Cameroon

关键词: Folic acid supplementation;    Hyperhomocysteinemia;    Inflammatory biomarkers;    Prevention;    Cardiovascular diseases;    Rheumatoid arthritis;   

Others  :  1224046
DOI  :  10.1186/s40364-015-0049-9

 received in 2015-05-22, accepted in 2015-08-21,  发布年份 2015

【 摘 要 】

Rheumatoid arthritis (RA) is a chronic inflammatory disease that preferentially affects joints, and characterized by an approximately two-fold increased risk of cardiovascular diseases compared with the general population. Beyond classical cardiovascular risk factors, systemic inflammatory markers are primarily involved. Hence, anti-inflammatory strategies such as homocysteine-lowering interventions are warranted. Indeed, hyperhomocysteinemia is commonly found in RA patients as a result of both genetic and non-genetic factors including older age, male gender, disease-specific features and disease-modifying antirheumatic drugs. Most importantly in the pathophysiology of hyperhomocysteinemia and its related cardiovascular diseases in RA, there is a bi-directional link between immuno-inflammatory activation and hyperhomocysteinemia. As such, chronic immune activation causes B vitamins (including folic acid) depletion and subsequent hyperhomocysteinemia. In turn, hyperhomocysteinemia may perpetrate immuno-inflammatory stimulation via nuclear factor ƙappa B enhancement. This chronic immune activation is a key determinant of hyperhomocysteinemia-related cardiovascular diseases in RA patients. Folate, a homocysteine-lowering therapy could prove valuable for cardiovascular disease prevention in RA patients in the near future with respect to homocysteine reduction along with blockade of subsequent oxidative stress, lipid peroxidation, and endothelial dysfunction. Thus, large scale and long term homocysteine-lowering clinical trials would be helpful to clarify the association between hyperhomocysteinemia and cardiovascular diseases in RA patients and to definitely state conditions surrounding folic acid supplementation. This article reviews direct and indirect evidence for cardiovascular disease prevention with folic acid supplementation in RA patients.

【 授权许可】

   
2015 Essouma and Noubiap.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Barber CEH, Smith A, Esdaile JM, Barnabe C, Martin OM, Faris P et al.. Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators. Arthritis Care Res. 2015; 67(2):169-79.
• [2]Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014; 16:435. BioMed Central Full Text
• [3]Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatol (Oxf). 2009;. doi:10. 1093/rheumatology/kep252. webcite
• [4]De Bree A, Verschuren WMM, Kromhout D, Kluijtmans LAJ, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002; 54(4):599-618.
• [5]Khandanpour L, Loke YK, Meyer FJ, Jennings B, Armon MP. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2009; 38:316-22.
• [6]Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS, Herrera-Diaz S, Anaya J-M, Rojas-Villaraga A. Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis. 2012; 2012:371909.
• [7]Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M et al.. Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases? Lupus. 2007; 16:852-62.
• [8]Fujimaki C, Hayashi H, Tsubois S, Matsuyama T, Kosuge K, Yamada H et al.. Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C > T genetic polymorphism in Japanese patients with rheumatoid arthritis. Biomarkers. 2009; 14(1):49-54.
• [9]Lopez-Olivo MA O, Gonzalez-Lopez L, Garcia-Gonzalez A, Villa-Manzano AI, Cota-Sanchez AR, Salazar-Paramo M et al.. Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol. 2006; 35:112-6.
• [10]Berglund S, Wållberg Jonsson S, Rantapää DS. Atherothrombotic events in rheumatoid arthritis are predicted by homocysteine - a six-year follow-up study. Clin Exp Rheumatol. 2009; 27(5):822-5.
• [11]Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M et al.. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev. 2007; 6:503-9.
• [12]Schroecksnadel K, Frick B, Kaser S, Wirleitner B, Ledochowski M, Mur E et al.. Moderate hyperhomocysteinaemia and immune activation in patients with rheumatoid arthritis. Clin Chim Acta. 2003; 338:157-64.
• [13]Turiel M, Atzeni F, Tomasoni L, de Portu S, Delfino L, Bodini BD et al.. Non-invasive assessment of coronary flow reserve and ADMA levels: a case–control study of early rheumatoid arthritis patients. Rheumatol (Oxf). 2009; 48:834-9.
• [14]Woolf K, Manore MM. Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis. J Am Diet Assoc. 2008; 108:443-53.
• [15]Visentin M, Diop-Bove N, Zhao R, Goldman ID. The intestinal absorption of folates. Annu Rev Physiol. 2014; 76:251-74.
• [16]Kunisawa J, Hashimoto E, Ishikawa I, Kiyono H. A pivotal role of vitamin B9 in the maintenance of regulatory T cells in vitro and in vivo. PLoS One. 2012; 7(2):e32094.
• [17]Seetharam B, Alpers DH. Absorption and transport Of cobalamine (vitamine B12). Ann Rev Nutr. 1982; 2:343-69.
• [18]Albersen M, Bosma M, Knoers NVVAM, de Ruiter BHB, Diekman EF et al.. The intestine plays a substantial role in human vitamin B6 metabolism: a caco-2 cell model. PLoS One. 2013; 8(1):e54113.
• [19]Nissinen R, Leirisalo-Repo M, Nieminen AM, Halme L, Fa¨rkkila¨ M, Palosuo T et al.. Immune activation in the small intestine in patients with rheumatoid arthritis. Ann Rheum Dis. 2004; 63:1327-30.
• [20]Yeoh N, Burton JP, Suppiah P, Reid G, Stebbings S. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep. 2013; 15:314.
• [21]Seriolo B, Fasciolo D, Sulli A, Cutolo M. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol. 2001; 19:561-4.
• [22]Olech E, Merill JT. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Cur Rheumatol Rep. 2006; 8:100-8.
• [23]Whittle SL, Huhghes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatol (Oxf). 2004; 43:267-71.
• [24]Haagsma CJ, Blom HJ, van Riel PLCM, van’t Hof MA, Giesendorf BAJ, van Oppenraaij-Emmerzaal D et al.. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 1999; 58:79-84.
• [25]Van Ede AE, Laan RFJM, Blom HJ, Boers GHJ, Haagsma CJ, Thomas CMG et al.. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatol (Oxf). 2002; 41:658-65.
• [26]Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009; 160:622-8.
• [27]Baggot JE, Morgan SL. Methotrexate catabolism to 7-hydroxy methotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplements. Arthritis Rheum. 2009; 60(8):2257-61.
• [28]Shea B, Swinden MV, Ghogomu ET, Orti Z, Katchamart W, Rader T et al.. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014; 41(6):1049-60.
• [29]Mendes RH, Mostarda C, Candido GO, Moraes-Silva IC, D’Almeida V, Bello-Klein A et al.. Moderate hyperhomocysteinemia provokes dysfunction of cardiovascular autonomic system and liver oxidative stress in rats. Autonomic Neuroscience: Basic and Clinical. 2014; 180:43-7.
• [30]De Bree A, van Mierlo LA, Draijer R. Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2007; 86:610-7.
• [31]Chen S, Li N, Deb-Chatterji M, Dong Q, Kielsten JT, Weissenborn K et al.. Asymmetric dimethyarginine as marker and mediator in ischemic stroke. Int J Mol Sci. 2012; 13:15983-6004.
• [32]Rocha MS, Teerlink T, Janssen MCH, Kluijtman LAS, Smulders Y, Jakobs C et al.. Asymmetric dimethylarginine in adults with cystathionine-synthase deficiency. Atheroscler. 2012; 222:509-11.
• [33]Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B et al.. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res. 2003; 57:244-52.
• [34]Prati C, Demougeot C, Guillot X, Godfrin-Valnet M, Wendling D. Endothelial dysfunction in joint disease. Joint Bone Spine. 2014; 81:386-91.
• [35]Gotto AM. Jeremiah Metzger lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? Trans Am Clin Climatol Assoc. 2011; 122:256-89.
• [36]Zhou S, Zhang Z, Xu G. Notable epigenetic role of hyperhomocysteinemia in atherogenesis. Lipids in Health and Dis. 2014; 13:134. BioMed Central Full Text
• [37]Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “High-Grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003; 108:2957-63.
• [38]Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005; 35:8-17.
• [39]Bouchti IE, Sordet C, Kuntz J-L, Sibilia J. Severe atherosclerosis in rheumatoid arthritis and hyperhomocysteinemia: is there a link? Joint Bone Spine. 2008; 75:499-501.
• [40]Anan F, Masaki T, Tatsukawa H, Nagano S, Oribe M, Eshima N et al.. The role of homocysteine as a significant risk factor for white matter lesions in Japanese women with rheumatoid arthritis. Metabol Clin Exp. 2009; 58:69-73.
• [41]Dala AG, Ibrahim WA, Taha AA, Alsheikh NM. Is silent ischemic heart disease evident in rheumatoid arthritis patients? Life Sci J. 2012; 9(3):927-34.
• [42]Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T et al.. Increased coronary-artery atherosclerosis in rheumatoid arthritis relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005; 52(10):3045-53.
• [43]Cisternas M, Gutierrez MA, Klaassen J, Acosta AM, Jacobelli S. Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol. 2002; 29:1619-22.
• [44]Eren E, Ellidag HY, Aydin O, Yılmaz N. HDL-associated paraoxonase 1 as a bridge between postmenopausal osteoporosis and cardiovascular disease. Chonnam Med J. 2014; 50:75-81.
• [45]Kaplan MJ. Cardiovascular complications of rheumatoid arthritis -assessment, prevention and treatment. Rheum Dis Clin North Am. 2010; 36(2):405-26.
• [46]El-Banna H, Jiman-Fatani A. Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis. BMC Musculoskelet Disord. 2014; 15:379. BioMed Central Full Text
• [47]Profumo E, Di Franco M, Buttari B, Masella R, Filesi C, Tosti ME et al.. Biomarkers of subclinical atherosclerosis in patients with autoimmune disorders. Mediators Inflamm. 2012; 2012:503942.
• [48]Surdacki A, Martens-Lobenhoffer J, Wloch A, Marewicz E, Rakowski T, Wieczorek-Surdacka E et al.. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atheroclerosis in rheumatoid arthritis. Arthritis Rheum. 2007; 56(3):809-19.
• [49]Asanuma Y, Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T et al.. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atheroscler. 2007; 195(2):e135-41.
• [50]Ying G, Wang Y, Cen X-m, Yang M, Liang Y, Xie Q-B. Lipid peroxidation-mediated inflammation promotes cell apoptosis through activation of NF-κB pathway in rheumatoid arthritis synovial cells. Mediators Inflamm. 2015; 2015:460310.
• [51]Glant TT, Mikecz K, Rauch TA. Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med. 2014; 12:35. BioMed Central Full Text
• [52]El-Swefy SE, Ali SI, Asker ME, Mohamed HE. Hyperhomocysteinaemia and cardiovascular risk in female ovariectomized rats: role of folic acid and hormone replacement therapy. J Pharm Pharmacol. 2002; 54:391-7.
• [53]Lee H, Kim J-m, Kim HJ, Lee I, Chang N. Folic acid supplementation can reduce the endothelial damage in rat brain microvasculature due to hyperhomocysteinemia. J Nutr. 2005; 135:544-8.
• [54]França CF, Vianna LM. Effectiveness of B vitamins on the control of hypertension and stroke events of SHRSP rats. J Diet Suppl. 2010; 7(1):71-7.
• [55]Yang H-T, Lee M, Hong K-S, Ovbiagele B, Saver JL. Efficacy of folic acid supplementation in cardiovascular disease prevention: An updated meta-analysis of randomized controlled trials. Eur J Int Med. 2012; 23:745-54.
• [56]Huo H, Qin X, Wang J, Sun N, Zeng Q, Xu X et al.. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis. Int J Clin Pract. 2012; 66(6):544-51.
• [57]Huo Y, Li J, Qin X, Huan Y, Wang X, Gottesman RF. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China the CSPPT randomized clinical trial. JAMA. 2015; 313(13):1325-35.
• [58]Clarke R, Halsey J, Bennett D, Lewington S. Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. J Inherit Metab Dis. 2011; 34:83-91.
• [59]Mei W, Rong Y, Jinming L, Yongjun L, Hui Z. Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomized controlled trials. Int J Clin Pract. 2010; 64(2):208-15.
• [60]den Heijer M, Willems HPJ, Blom HJ, Gerrits WBJ, Cattaneo M, Eichinger S et al.. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood. 2007; 109:139-44.
• [61]Qin X, Fan F, Cui Y, Chen F, Chen Y, Cheng X et al.. Folic acid supplementation with and without vitamin B6 and revascularization risk: a meta-analysis of randomized controlled trials. Clin Nutr. 2014; 33:603e612.
• [62]Joseph J, Handy DE, Loscalzo J. Quo Vadis: whither homocysteine research? Cardiovasc Toxicol. 2009; 9(2):53-63.
• [63]Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P et al.. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74:480-9.
• [64]De Vecchis R, Baldi C, Palmisani L. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. Anatolian J Cardiol. 2015; 15(0). doi:10. 5152/akd.2015.6136. webcite
• [65]Micha R, Imamura F, Ballmoos MW, Solomon DH, Herman MA, Ridker PM et al.. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011; 108(9):1362-70.
• [66]Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate treatment and mortality in rheumatoid arthritis. Lancet. 2002; 360:1097-8.
• [67]Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol. 2001;30:305–7.
• [68]Aviña-Zubieta JA, Thomas JA, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012; 71:1524-9.
• [69]Holc I, Hojs R, Cikeš N, Ambrožič A, Cučnik S, Kveder T et al.. Antiphospholipid antibodies and atherosclerosis: insights from rheumatoid arthritis – a five-year follow-up study. Immunobiol. 2011; 216:1331-7.
• [70]Qin X, Xu M, Zhang Y, Li J, Xu X, Wang X et al.. Effect of folic acid supplementation on the progression of carotid intima-media thickness: A meta-analysis of randomized controlled trials. Atherosclers. 2012; 222:307-13.
• [71]Kiech L, Laxton RC, Xiao Q, Hernesniemi JA, Raitakari OT, Kähönen M et al.. Coronary artery disease–related genetic variant on chromosome 10q11 is associated with carotid intima-media thickness and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30:2678-83.
• [72]Tyrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness. A systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2010; 30:1014-26.
• [73]Hollan I, Dessein PH, Ronda N, Wasko MC, Svenungsson E, Agewall S, et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev. 2015;. http://dx. doi.org/10.1016/j.autrev.2015.06.004. webcite